image
Healthcare - Medical - Diagnostics & Research - NASDAQ - DE
$ 5.2969
1.28 %
$ 11.8 M
Market Cap
-0.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one MYNZ stock under the worst case scenario is HIDDEN Compared to the current market price of 5.3 USD, Mainz Biomed B.V. is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one MYNZ stock under the base case scenario is HIDDEN Compared to the current market price of 5.3 USD, Mainz Biomed B.V. is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one MYNZ stock under the best case scenario is HIDDEN Compared to the current market price of 5.3 USD, Mainz Biomed B.V. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
895 K REVENUE
69.00%
-26.6 M OPERATING INCOME
-1.80%
-26.3 M NET INCOME
0.35%
-21.9 M OPERATING CASH FLOW
-48.54%
-1.9 M INVESTING CASH FLOW
-188.37%
14.2 M FINANCING CASH FLOW
-40.58%
215 K REVENUE
-57.07%
-6.59 M OPERATING INCOME
49.21%
-5.18 M NET INCOME
37.18%
-4.66 M OPERATING CASH FLOW
9.06%
-374 K INVESTING CASH FLOW
-202.76%
3.47 M FINANCING CASH FLOW
-36.04%
Balance Sheet Mainz Biomed B.V.
image
Current Assets 8.98 M
Cash & Short-Term Investments 7.07 M
Receivables 355 K
Other Current Assets 1.55 M
Non-Current Assets 6.43 M
Long-Term Investments 0
PP&E 3.03 M
Other Non-Current Assets 3.39 M
Current Liabilities 9.24 M
Accounts Payable 2.33 M
Short-Term Debt 5.22 M
Other Current Liabilities 1.69 M
Non-Current Liabilities 2.92 M
Long-Term Debt 2.2 M
Other Non-Current Liabilities 727 K
EFFICIENCY
Earnings Waterfall Mainz Biomed B.V.
image
Revenue 895 K
Cost Of Revenue 386 K
Gross Profit 510 K
Operating Expenses 27.2 M
Operating Income -26.6 M
Other Expenses -349 K
Net Income -26.3 M
RATIOS
56.91% GROSS MARGIN
56.91%
-2975.47% OPERATING MARGIN
-2975.47%
-2936.50% NET MARGIN
-2936.50%
-809.29% ROE
-809.29%
-170.65% ROA
-170.65%
-233.79% ROIC
-233.79%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Mainz Biomed B.V.
image
Net Income -26.3 M
Depreciation & Amortization 866 K
Capital Expenditures -1.9 M
Stock-Based Compensation 4.01 M
Change in Working Capital -64.6 K
Others -751 K
Free Cash Flow -23.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Mainz Biomed B.V.
image
MYNZ has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Mainz Biomed B.V.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Mainz Biomed Expands into Switzerland with labor team w BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 1 week ago
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 2 weeks ago
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that on January 23, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that it has regained compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market set forth in Listing Rule 5550(b)(1). globenewswire.com - 1 month ago
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients Multi-center study expected to complete enrollment in the second half and reporting in the Fourth Quarter of 2025 BERKELEY, Calif. and MAINZ, Germany, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the launch of eAArly DETECT 2, a U.S. feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over a population of approximately 2,000 patients, all of average risk, to validate the industry leading results of previous feasibility studies, which included average risk and identified risk patients. globenewswire.com - 1 month ago
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 2 months ago
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 2 months ago
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 2 months ago
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3. benzinga.com - 2 months ago
Mainz Biomed Announces Stock Split BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 3 months ago
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 4 months ago
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert globenewswire.com - 4 months ago
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 5 months ago
8. Profile Summary

Mainz Biomed B.V. MYNZ

image
COUNTRY DE
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 11.8 M
Dividend Yield 0.00%
Description Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Contact Robert Koch Strasse 50, Mainz, 55129 https://mainzbiomed.com
IPO Date Nov. 5, 2021
Employees 65
Officers Dr. Moritz Eidens Ph.D. Chief Science Officer & Executive Director Stefan Erlach Head of Human Resources Dr. Frank Krieg-Schneider Chief Technology Officer Mr. William J. Caragol CPA Chief Financial Officer Mr. Guido Baechler Chief Executive Officer & Executive Director Dr. Christopher Von Torne P.M.P., Ph.D. Chief Operating Officer Mr. Philipp Freese Chief Business Officer